| 01/20 | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PR |
| 01/18 | Avidity Biosciences Says it Received FDA's Fast Track Designation for AOC 1020 to Treat.. | MT |
| 01/18 | Avidity Biosciences Gets FDA Fast-Track Designation for AOC 1020 | DJ |
| 01/18 | Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment o.. | PR |
| 01/18 | Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment o.. | CI |
| 01/06 | Avidity Biosciences : January 2023 Corporate Presentation | PU |
| 01/04 | Wells Fargo Adjusts Price Target on Avidity Biosciences to $55 From $60, Maintains Over.. | MT |
| 01/03 | Insider Sell: Avidity Biosciences | MT |
| 2022 | Avidity Biosciences, Inc. : Other Events, Financial Statements and Exhibits (form 8-K) | AQ |
| 2022 | Avidity Biosciences Prices Common Stock Offering at $17.25 Per Share | MT |
| 2022 | Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock | PR |
| 2022 | Credit Suisse Adjusts Price Target on Avidity Biosciences to $35 From $33 After 'Largel.. | MT |
| 2022 | Raymond James Adjusts Avidity Biosciences Price Target to $71 From $30, Maintains Stron.. | MT |
| 2022 | Avidity Biosciences Plans Public Offering of Common Stock | MT |
| 2022 | Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock | PR |
| 2022 | Sector Update: Health Care Stocks Stage Small Recovery Late | MT |
| 2022 | Avidity Biosciences : December 2022 Corporate Presentation | PU |
| 2022 | Sector Update: Health Care Stocks Posting Moderate Gains | MT |
| 2022 | Top Midday Gainers | MT |
| 2022 | Stocks Remain Relatively Flat as Investors Wait for Fed Rate-Hike Move | MT |
| 2022 | Sector Update: Health Care Stocks Narrowly Mixed Pre-Bell Wednesday | MT |
| 2022 | Avidity Biosciences Says Data From Preliminary Assessment of AOC 1001 Shows 'Targeted D.. | MT |
| 2022 | Top Premarket Gainers | MT |
| 2022 | Avidity Biosciences, Inc. : Regulation FD Disclosure, Other Events, Financial Statements a.. | AQ |
| 2022 | Avidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ev.. | PR |
| 2022 | Avidity Biosciences, Inc. Announces Positive AOC 1001 Phase 1/2 Marina(Tm) Data Demonst.. | CI |
| 2022 | Avidity Biosciences, Inc. : Change in Directors or Principal Officers (form 8-K) | AQ |
| 2022 | Credit Suisse Adjusts Avidity Biosciences' Price Target to $33 From $32, Keeps Outperfo.. | MT |
| 2022 | Raymond James Adjusts Price Target on Avidity Biosciences to $30 From $29, Maintains St.. | MT |
| 2022 | AVIDITY BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION .. | AQ |
| 2022 | Avidity Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Month.. | CI |
| 2022 | Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights | PR |
| 2022 | Avidity Biosciences to Participate in Upcoming Investor Conferences | PR |
| 2022 | Avidity Biosciences, Inc. : Other Events (form 8-K) | AQ |
| 2022 | Avidity Biosciences, Inc. Announces Planned Explore44 Trial of AOC 1044 in Healthy Volu.. | CI |
| 2022 | Avidity Biosciences Launches Phase 1/2 trial of AOC 1044 to Treat Duchenne Muscular Dys.. | MT |
| 2022 | Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne.. | PR |
| 2022 | Avidity Biosciences, Inc. Announces Phase 1/2 EXPLORE44 Trial of AOC 1044 for Duchenne .. | CI |
| 2022 | Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annua.. | PR |
| 2022 | Avidity Biosciences, Inc. : Other Events (form 8-K) | AQ |
| 2022 | Avidity Biosciences, Inc. Plans FORTITUDE Trial of AOC 1020 | CI |
| 2022 | Avidity Biosciences : October 2022 Corporate Presentation | PU |
| 2022 | Avidity Biosciences Announces the Phase 1/2 FORTITUDE Trial of AOC 1020 in Adults with .. | AQ |
| 2022 | Avidity Biosciences Launches Phase 1/2 Trial of AOC 1020 in Adults With Facioscapulohum.. | MT |
| 2022 | Avidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adult.. | PR |
| 2022 | Avidity Biosciences Announces the Phase 1/2 Fortitude(Tm) Trial of AOC 1020 in Adults w.. | CI |
| 2022 | Jabil, Hertz rise; Avidity, Provident Financial fall | AQ |
| 2022 | Sector Update: Health Care Stocks Edging Lower This Afternoon | MT |
| 2022 | Chardan Research Adjusts Price Target for Avidity Biosciences to $27 From $29, Maintain.. | MT |
| 2022 | Top Midday Decliners | MT |
| 2022 | Sector Update: Health Care Stocks Slipping Despite Biotechs Maintaining Ea.. | MT |
| 2022 | Avidity Biosciences : September 2022 Corporate Presentation | PU |
| 2022 | Wall Street Set to Open Higher Ahead of Consumer Confidence, New Home Sales Reports | MT |
| 2022 | Sector Update: Health Care Stocks Climb Pre-Bell Tuesday | MT |
| 2022 | Sector Update: Health Care | MT |
| 2022 | US Futures, Oil Climb Higher | MT |
| 2022 | Avidity Biosciences Shares Slide on Partial FDA Study Hold | DJ |
| 2022 | U.S. FDA puts Avidity's muscle disorder drug trial on partial hold | RE |
| 2022 | Avidity Biosciences Gets FDA Partial Clinical Hold on New Participant Enrollment in MAR.. | MT |
| 2022 | U.S. FDA puts Avidity's muscle disorder drug study on hold | RE |
| 2022 | Avidity Biosciences, Inc. : Other Events (form 8-K) | AQ |
| 2022 | Avidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment i.. | PR |
| 2022 | Avidity Biosciences, Inc. Announces FDA Partial Clinical Hold on New Participant Enroll.. | CI |
| 2022 | Avidity Biosciences : FDA Places Partial Hold on AOC 1001 Study | DJ |
| 2022 | Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy.. | PR |
| 2022 | Avidity Biosciences to Participate in Upcoming Investor Conferences | PR |
| 2022 | Avidity Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights | PR |
| 2022 | Avidity Biosciences : Reports Second Quarter 2022 Financial Results and Recent Highlights .. | PU |
| 2022 | AVIDITY BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION .. | AQ |
| 2022 | Avidity Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Month.. | CI |
| 2022 | Avidity Biosciences Starts Patient Enrollment in Phase 2 Study of Proposed Neuromuscula.. | MT |
| 2022 | Avidity Biosciences : August 2022 Corporate Presentation | PU |
| 2022 | Avidity Biosciences Enrolls Patients in the MARINA™ Open-Label Extension Study | PR |
| 2022 | Avidity Biosciences, Inc. Enrolls Patients in the Marina(Tm) Open-Label Extension Study | CI |
| 2022 | Avidity Biosciences Shares Rise After Chardan Research Initiates Coverage | MT |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
